The sum was factored into the company’s sales and earnings outlook for the year, he said. Meanwhile, Pfizer expanded its ...

Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research ...

After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it can ...

Pfizer’s pipeline is robust, with RSV vaccine expansions and AI-driven R&D enhancing long-term prospects. Cost-cutting measures, including manufacturing optimization, improved adjusted gross ...

U.S. President Donald Trump signed a wide-reaching executive order on Monday directing drugmakers to lower the prices of ...

Pfizer on Tuesday reaffirmed its outlook for ... The company launched its multiyear cost-cutting plan in 2023 after the drugmaker miscalculated demand for its Covid-19 products.